JAAD Case Reports · 2018 · 16 citations · 6 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationTargeted Cancer TherapyTargeted TherapyImmune Checkpoint ResponseImmune System ModulationMetastatic Melanoma TreatmentPd-1 SignalingPembrolizumab TherapyProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-1 Blockade
Pembrolizumab is an anti–programmed cell death receptor protein-1 (PD-1) monoclonal antibody first approved in 2014 by the US Food and Drug Administration for the treatment of metastatic melanoma. Pembrolizumab targets the PD-1, blocking the immune checkpoint and subsequently boosting the immune response against cancerous cells. Although effective against systemic disease, anti–PD-1 therapy is also associated with adverse effects such as vitiligo and pruritus caused by overstimulation and hyperproliferation of the immune system.
6
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, Igor Vujic, Adil Daud et al. · JAMA Dermatology · 2015 · 452 citations · Full text
Medicine, Oncology, Pharmacology +15
Pembrolizumab-associated sarcoidosis
Jonathan Cotliar, Christiane Querfeld, William J. Boswell et al. · JAAD Case Reports · 2016 · 88 citations · Full text
Life Sciences, Immunology, Oncology +17